item management s discussion and analysis of financial condition and results of operations since inception  the company has been primarily engaged in research and development 
to date  cambridge neuroscience has not received any revenue from the sale of products 
the company has not been profitable since inception and expects to incur substantial operating losses for at least the next several years 
cambridge neuroscience has financed its operations through proceeds from an initial public offering and a follow on public offering in  various private placements of preferred equity securities prior to the initial public offering  a private placement of common stock to institutional investors in  its collaboration with bi which commenced in march  two directed public offerings in  its collaboration with allergan which commenced in november  research grants and investment income earned on its cash balances and short term investments 
in  the company entered into a collaboration with bi for the development and commercialization of cerestat 
the company received million upon signing the agreement  consisting of million in the form of an expense reimbursement and million for  shares of the company s common stock 
in september  pursuant to the agreement  bi purchased an additional  shares of the company s common stock for million 
pursuant to the collaboration  bi will fund of the development costs for cerestat in the united states and europe and all of the development costs in japan  and the company is entitled to receive royalties on product sales 
the company has the option to co promote in the united states 
any co promotion activities by the company will result in increased sales and marketing and general and administrative expenditures 
in november  the company entered into a collaboration with allergan for the development of nmda ion channel blockers  sodium ion channel blockers and combination ion channel blockers for the treatment of ophthalmic disorders  including glaucoma 
in conjunction with the signing of this agreement  the company received million for  shares of the company s common stock 
allergan will bear all of the development costs for potential products arising from the collaboration  and the company is entitled to receive royalties on any product sales 
results of operations years ended december  and revenues research and development revenue decreased to million for the year ended december  from million for the year ended december   a decrease of million 
revenue in included the receipt of million in march upon the signing of the collaboration agreement with bi  representing reimbursement of previously incurred cerestat costs 
of the total research and development revenue under the bi agreement  revenue relating to current period spending was million in  compared to million in  a decrease of million 
this decrease was due to an increase in spending by bi relative to the amount spent in the fiscal period by both companies 
the company recognizes revenue from the bi collaboration in the amount that its cerestat development expenses exceed of the cerestat development expenses of the company and bi combined 
in november  the company entered into a collaboration agreement with allergan for the development of treatments for ophthalmic disorders  including glaucoma 
revenue in includes  received pursuant to the allergan collaboration 
operating expenses operating expenses increased to million for the year ended december   from million for the same period in  an increase of  research and development expenses of million in were comparable to those incurred in during  the company began a phase iii clinical trial of cerestat in tbi 
it is expected that as more patients enroll in this trial and the phase iii stroke trial being conducted by bi  total costs borne by the company will increase 
the company expects to incur significant expenses related to these trials in and thereafter  subject to the terms of the cost sharing arrangement with bi 
in addition  continued activity relating to the development of the company s other product development programs is expected to contribute to an increase in research and development expenses 
research and development expenses were of total operating expense in  compared to in general and administrative expenses increased to million in the year ended december   from million in the same period in  an increase of  this increase is due to the costs associated with higher headcount in  primarily in support of the company s business development and investor relations activities 
interest income interest income was million for the year ended december   compared to  in the same period in  an increase of  this increase reflects the higher cash balances available for investment during  primarily due to the proceeds from issuances of common stock in the fourth quarter of and the proceeds received in pursuant to the second equity investment by bi 
net loss per share the net loss for the year ended december  increased to million  or per share  from million  or per share  for the same period in this increase in net loss per share was due primarily to the decrease in research and development revenue  offset in part by an increase in the weighted average shares outstanding from million for the year ended december  to million for the same period in years ended december  and revenues research and development revenue was million for the year ended december  the company had no research and development revenue for the year ended december  the revenue in was received in connection with the company s collaboration with bi and included a one time reimbursement of million for previously incurred cerestat research and development costs 
revenue from government grants decreased to  from  for the year ended december   a decrease of  due to the expiration of a grant in march operating expenses total operating expenses increased to million for the year ended december   from million for the year ended december  research and development expenses increased to million for the year ended december  from million for the year ended december  costs associated with cerestat preclinical studies and clinical trials increased to million for the year ended december  from million for the year ended december   an increase of million 
partially offsetting this increase were lower costs associated with a decrease in workforce as part of a cost reduction program implemented in january as well as lower external costs associated with the company s other research and development programs 
research and development expenses were of total operating expenses for the year ended december   compared to for the year ended december  general and administrative expenses decreased to million in the year ended december  from million for the year ended december   a decrease of  this decrease is due primarily to cost savings associated with the reduction in workforce in january as well as to a decrease in expenses relating to the use of outside consultants for business development purposes 
interest income interest income increased to  for the year ended december  from  for the year ended december   an increase of  this was due to an increase in the rate of return earned on the company s investments as well as to higher cash balances available for investment in net loss per share the net loss for the year ended december  was million  or per share  compared to million  or per share  for the year ended december  the decrease in the net loss is primarily due to increased research and development revenues 
liquidity and capital resources the company had cash and cash equivalents of million at december   compared to million at december  pursuant to the terms of the collaboration agreement with bi and in connection with the commencement of the pivotal stroke trial by bi  the company received a milestone payment in september of million  before related costs of  in exchange for  shares of the company s common stock 
in addition  in the company received million in advances against reimbursable expenses pursuant to the bi collaboration  of which million was recognized as research and development revenue in the difference between advances received and revenue recognized is recorded as research and development advances and may be subject to repayment to bi 
in november  the company entered into a collaboration agreement with allergan for the development of treatments for ophthalmic disorders  including glaucoma 
upon signing the agreement  the company received million in exchange for  shares of the company s common stock 
at december   the company had received  from allergan  pursuant to the funding agreement  of which  was recognized as revenue in in  the company used million for operating purposes and  for the purchase of equipment  furniture and fixtures 
the company and bi began two large clinical trials in these trials are expected to involve approximately  patients and are expected to result in an increase in the company s consumption of capital 
the cost of both trials will be shared by the company and bi in accordance with the terms of the collaboration agreement 
the company s obligation relative to this sharing of costs is generally of total costs incurred by both parties  excluding development costs for japan which will be borne solely by bi 
any costs incurred in excess of one party s contractual obligation will be reimbursed by the other party 
the cash reimbursement and the revenue earned are subject to each party s relative expenditures and therefore may fluctuate on a quarterly basis 
the agreement provides that bi will advance cash to the company on a quarterly basis in the event that it is expected that the company will spend more than obligated under the agreement of total amount spent by both parties 
due to the uncertainty associated with the annual estimate of spending by both companies and the timing of the relative spending  the amount and timing of advances is uncertain 
on an annual basis  actual spending is reconciled with the budget and may result in the company s repayment to bi of any excess advances 
it is expected that as more patients enroll in these trials  total costs and the costs borne by the company will increase 
there can be no assurance  therefore  that the company will receive further advances from bi in accordance with the cost sharing arrangement 
the company expects to incur significant expense related to these trials in and thereafter  subject to the cost sharing arrangement discussed above 
pursuant to the collaboration agreement with allergan  the company may receive an additional million in research and development funding over the next three years 
at december   the company had received  pursuant to this funding arrangement  of which  was recognized as revenue in in december  the company formed a subsidiary  cambridge neuroscience  partners  inc cnpi  which will pursue the development of treatments for alzheimer s disease and other neurological diseases  disorders or injuries 
cnpi has entered into a collaboration with the j 
david gladstone institutes gladstone 
pursuant to this collaboration agreement  gladstone will conduct a research program over a three year period  for which cnpi will provide at least million in funding per year 
the company owns of the outstanding stock of cnpi and has guaranteed cnpi s obligations with respect to its collaboration with gladstone 
in february  the company received million in proceeds  before related costs of  from a public offering of  shares of common stock at per share 
the company believes that the existing cash and cash equivalents available at december  together with the net proceeds from the public offering will be sufficient to maintain operations at least through mid the bi and allergan collaborations also provide that the company may receive up to an additional million and up to an additional million  respectively  upon the achievement of certain milestones 
however  there can be no assurance as to when or if these milestones will be achieved 
the company s primary expenditures are expected to be in the areas of research and development  general and administrative expenses  and capital expenditures 
the company will require substantial additional funds for its research and product development programs  pursuing regulatory clearances  establishing production  sales and marketing capabilities and other operating expenses 
despite the potential future milestone payments under the bi and allergan agreements  adequate funds for these purposes may not be available when needed on terms acceptable to the company 
insufficient funds may require the company to delay  scale back or eliminate certain of its research and product development programs or to license third parties to commercialize products or technologies that the company might otherwise undertake itself 
the company does not believe that inflation has had a material impact on its results of operations 
the discussion contained in this section as well as elsewhere in this annual report on form k may contain forward looking statements based on the current expectations of the company s management 
such statements are subject to certain risks and uncertainties which could cause actual results to differ materially from those projected 
see important factors regarding forward looking statements attached hereto as exhibit and incorporated by reference into this form k 
readers are cautioned not to place undue reliance on these forward looking statements which speak only as of the date hereof 
the company undertakes no obligation to publicly release the result of any revisions to these forward looking statements which may be made to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events 

